ArticleHeart and vessels2026
Clinical course after cardiac resynchronization therapy in transthyretin amyloid cardiomyopathy receiving disease-modifying therapy.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring the Electrical Phenotype of Transthyretin Amyloid Cardiomyopathy in the Era of Disease-Modifying Therapy.Circulation reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical course of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) undergoing cardiac resynchronization therapy (CRT) remains insufficiently characterized, particularly in the era of disease-modifying therapy (DMT). We aimed to describe the clinical, electrocardiographic, echocardiographic, and long-term outcomes of ATTR-CM patients treated with CRT while receiving tafamidis or patisiran. This single-center retrospective study included 12 patients with ATTR-CM who underwent CRT between March 2020 and May 2024. All patients received DMT. After CRT implantation, QRS duration significantly decreased (161.3 ± 18.6 vs. 134.3 ± 16.8 ms, P = 0.0003). Improvement in New York Heart Association functional class was observed, although it did not reach statistical significance (P = 0.063). Marked echocardiographic reverse remodeling, including reductions in end-systolic volume and improvement in left ventricular ejection fraction, was not observed; however, echocardiographic parameters remained largely stable during follow-up. During a mean follow-up of 800 ± 97 days, MACCE occurred in 2 of 12 patients (16.7%), both representing hospitalizations for heart failure. In this contemporary series of ATTR-CM patients receiving DMT, CRT was associated with QRS narrowing, while clinical and echocardiographic status remained largely stable during follow-up, despite limited evidence of reverse remodeling. Because the effects of CRT could not be disentangled from those of concomitant DMT, these findings should be interpreted as descriptive and hypothesis-generating. This study does not qualify as a clinical trial, and it is a retrospective analysis and not classified as an interventional investigation.
Indexed as
Identifiers
42228078What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.